Study Notes on AI in Drug Discovery & Development

AI IN DRUG DISCOVERY & DEVELOPMENT

Introduction

Artificial Intelligence (AI) is defined as computational systems capable of performing tasks typically requiring human intelligence, which includes recognizing patterns, learning from data, making predictions, and optimizing decisions. In the context of drug discovery, AI aims to enhance the efficiency, speed, cost-effectiveness, and success rates involved in the process of discovering and developing new medicines.
The traditional drug discovery process is characterized by the following challenges:

  • Time-consuming: The process can often take 10–15 years or more from initial concept to final approval.
  • Costly: It is often associated with expenditures reaching billions of dollars.
  • High Failure Rate: Many drug candidates fail at late-stages despite significant investments.
  • Data Heavy: The process is inundated with extensive data requirements.
  • Inefficient Screening of Large Chemical Space: The vast array of potential drug-like molecules makes manual screening impractical.
    AI seeks to rectify these inefficiencies and challenges present in traditional drug discovery.
Why AI is Needed in Drug Discovery
Traditional Pipeline Problems
  1. Time: Drug discovery typically spans over a decade from initial concept to regulatory approval.
  2. Cost: Many candidates face failures late in the pipeline after substantial investments have already been made.
  3. Attrition Rates: Several compounds entering development fail due to various reasons such as:
       - Poor efficacy
       - Toxicity issues
       - Pharmacokinetic challenges
       - Commercial viability concerns
  4. Huge Search Space: There are estimates of up to 106010^{60} or more possible drug-like molecules, making manual screening infeasible.
Areas Where AI Is Used
  1. Target Identification: AI algorithms analyze data sets including:
       - Genomics
       - Transcriptomics
       - Proteomics
       - Disease-specific databases
       - Literature to pinpoint proteins or pathways involved in particular diseases.
    Example: Identifying new signaling targets in cancer.
  2. Virtual Screening: AI can forecast which molecules are likely to interact with a target before they are synthesized or tested. This enables researchers to use AI for pre-selection of high-potential candidates rather than conducting millions of physical screenings.
    Benefits:
       - Faster results
       - Lower costs
       - Decreased wet lab experiment requirements
  3. Lead Optimization: Once a promising hit is identified, AI aids in enhancing several properties including:
       - Potency
       - Selectivity
       - Solubility
       - Permeability
       - Metabolic stability
       - Toxicity profile
       AI can recommend potential structural modifications to further enhance these characteristics.
  4. De Novo Drug Design: AI is capable of generating new drug candidates computationally. It proposes molecular structures predicted to bind effectively to specific targets while possessing drug-like characteristics. This entire process is commonly referred to as generative chemistry or generative AI design.
  5. ADMET Prediction: AI facilitates predictions regarding:
       - Absorption
       - Distribution
       - Metabolism
       - Excretion
       - Toxicity
       Early-stage prediction of these factors can prevent costly failures in later stages of drug development.
  6. Drug Repurposing: AI identifies new potential uses for existing or approved drugs.
    Benefits:
       - Lower risk involved
       - Faster developmental timelines
       - Utilization of existing safety data
    Example: Drug repurposing efforts during the COVID-19 pandemic.
  7. Clinical Development: AI can support various aspects of clinical development such as:
       - Patient recruitment
       - Biomarker stratification
       - Trial design
       - Outcome prediction
       - Monitoring of adverse events
Key Evidence of AI Growth

The lecture highlighted a notable increase in the following areas post-2015:

  • AI-related Journal Publications
  • Patents
  • Normalized Publication Volume
    This increase suggests that AI transitioned from a theoretical concept to practical industrial applications. The rise in patents is particularly significant since they indicate a commercial translation of AI technologies.
Why Both Patents + Publications Matter
  • If there is only a rise in papers: It may signal academic hype without real-world applicability.
  • A concurrent increase in patents indicates that the industry recognizes the genuine value of AI technology, thereby suggesting contributions to viable pipelines in drug discovery.
Reasons for Growth After 2015

Several factors likely contributed to this growth:

  • Enhanced computing power (availability of GPUs and cloud computing)
  • Increased biological data availability
  • Advancements in algorithm sophistication (deep learning techniques)
  • More affordable sequencing technologies
  • Improved chemical databases
  • Increased interest from investors in the field
AI Advantages in Drug Discovery

Some distinct advantages provided by AI in the drug discovery process include:

  • Accelerated identification of hits
  • Reduced costs associated with screening
  • Better prioritization of candidate molecules
  • Earlier predictions of potential toxicity
  • Reduced waste in synthesis processes
  • Lowered reliance on animal testing
  • Enhanced personalized treatments through improved precision medicine
Limitations of AI
  1. Garbage In, Garbage Out: Poor quality training data can lead to inaccurate predictions.
  2. Complexity of Biological Systems: A prediction of binding does not guarantee clinical efficacy.
  3. Bias: AI models may favor previously established chemistry, leading to possible blind spots in discovering novel compounds.
  4. Interpretability: Some complex deep learning models operate as 'black boxes', making them difficult to interpret.
  5. Experimental Validation Required: AI serves as an assistance tool rather than a replacement for empirical scientific methods.
AI Drugs in Trials

Currently, many purported AI-derived drugs are primarily AI-assisted rather than being entirely AI-generated. AI contributions generally involve:

  • Target selection
  • Hit discovery
  • Optimization
    Instead of independently creating new medicines.
Exam Summary

AI should be viewed primarily as an accelerator and support tool rather than a total replacement for human scientists throughout various stages of drug discovery.